华东医药(000963.SZ)：DR10624注射液药品临床试验申请获美国FDA批准

Core Viewpoint - The company announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received FDA approval for the clinical trial application of the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Company Summary - Zhejiang Daor Biotechnology Co., Ltd. is a subsidiary of the company [1] - The approved drug, DR10624, is intended for the treatment of severe hypertriglyceridemia (SHTG) [1] - The FDA approval allows the company to conduct clinical trials in the United States [1] Industry Summary - The approval of DR10624 indicates potential growth opportunities in the biotechnology sector, particularly in treatments for severe hypertriglyceridemia [1]